Andina III and EMMAC Life Sciences Limited said today they have mutually terminated negotiations regarding a proposed business combination. The parties signed a non-binding letter of intent on July 22, in which EMMAC was expected to trade on the NASDAQ. Both sides cited “challenging global economic conditions” among the reasons for terminating the deal. EMMAC bills itself as Europe’s largest independent cannabis company. Andina shareholders last week approved an extension of the SPAC’s deadline to close a deal. Andina was initially capitalized with a $100M IPO. Read more.
Related Posts
Tech-Focused Pono Capital Files for $100M IPO
The SPAC is led by CEO Dustin Shindo, who also serves as CEO of software company Junify, which operates in California and Japan.
Shares & Warrants of Capitalworks Emerging Markets Acquisition May Trade Separately Starting Tomorrow
Sectors of particular interest to the new SPAC include consumer and consumer technology, financial and business services, healthcare, and technology, media and telecom, or TMT in emerging markets.
Merida Merger I Adjourns Meeting & Leafly Vote Until Feb. 1
When announced in August, the transaction was expected to generate proceeds of up to $161.5 million for Leafly.
Vesper Healthcare Stock and Warrants to Trade Separately
Vesper said it intends to focus its search on companies in the pharmaceutical and healthcare sectors.